SGMO
SANGAMO THERAPEUTICS INC
stock OTC

Should be fun, management superglued the cards to their chests re the FDA meeting, but the cards'll get torn off in the coming months to see who wins and loses... Thinking this is a short, could see it going to "zero", but it's a typical zombie biotech. Management said on the last Jefferies call that the FDA requested additional data for the accelerated approval, but haven't said what that data is. My speculation is that it's head-to-head w/ Papzimeos. The earnings call yesterday they said that eligibility for accel. approval wasn't part of the "informal meeting" w/ the FDA, but that details on the "confirmatory trial" are expected "shortly." I suspect that trial is vs. papzimeos and (not detailed on the call, natch) and it will be required for approval. Hence, a CRL in Oct and mkt cap should be \~$5-10M. dMabs worth zero, everything else worth zero. Maybe will follow in footsteps of SGMO?

Should be fun, management superglued the cards to their chests re the FDA meeting, but the cards'll get torn off in the coming months to see who wins and loses... Thinking this is a short, could see it going to "zero", but it's a typical zombie biotech. Management said on the last Jefferies call that the FDA requested additional data for the accelerated approval, but haven't said what that data is. My speculation is that it's head-to-head w/ Papzimeos. The earnings call yesterday they said that eligibility for accel. approval wasn't part of the "informal meeting" w/ the FDA, but that details on the "confirmatory trial" are expected "shortly." I suspect that trial is vs. papzimeos and (not detailed on the call, natch) and it will be required for approval. Hence, a CRL in Oct and mkt cap should be \~$5-10M. dMabs worth zero, everything else worth zero. Maybe will follow in footsteps of SGMO?